Understanding why CLL patients stop responding to treatment, and options for salvage therapies

Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.